|
CA2734802C
(en)
*
|
2008-08-22 |
2016-05-31 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
AU2011240735B2
(en)
|
2010-04-13 |
2015-01-29 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
|
|
JP5959516B2
(ja)
|
2010-08-18 |
2016-08-02 |
ライフ テクノロジーズ コーポレーション |
電気化学的検出装置のためのマイクロウェルの化学コーティング法
|
|
KR101929593B1
(ko)
*
|
2010-10-25 |
2018-12-14 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
|
BR112013017316A2
(pt)
*
|
2011-01-04 |
2019-09-24 |
Novartis Ag |
compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
|
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
|
EA030465B1
(ru)
|
2011-07-01 |
2018-08-31 |
Новартис Аг |
Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
|
|
CA2840620A1
(en)
*
|
2011-07-01 |
2013-01-10 |
Novartis Ag |
Combination therapy
|
|
WO2013059634A1
(en)
|
2011-10-20 |
2013-04-25 |
The Regents Of The University Of California |
Use of cdk9 inhibitors to reduce cartilage degradation
|
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
CN104302620A
(zh)
|
2012-04-26 |
2015-01-21 |
弗朗西斯·泽维尔·塔瓦雷斯 |
内酰胺的合成
|
|
ES2710491T3
(es)
|
2012-06-28 |
2019-04-25 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
|
JP6155332B2
(ja)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
|
WO2014002058A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
WO2014002052A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
CN104603126B
(zh)
|
2012-06-28 |
2017-05-31 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
|
JP6238980B2
(ja)
|
2012-07-12 |
2017-11-29 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
CA3163776A1
(en)
|
2012-08-03 |
2014-02-06 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
|
EP3251673A1
(en)
|
2012-12-13 |
2017-12-06 |
IP Gesellschaft für Management mbH |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
|
EP2934515B1
(en)
|
2012-12-20 |
2018-04-04 |
Novartis AG |
A pharmaceutical combination comprising binimetinib
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
ES2798899T3
(es)
|
2013-02-25 |
2020-12-14 |
Novartis Ag |
Mutación novedosa del receptor de andrógenos
|
|
EP2970268A1
(en)
*
|
2013-03-13 |
2016-01-20 |
AbbVie Inc. |
Cdk9 kinase inhibitors
|
|
CN105189481A
(zh)
|
2013-03-13 |
2015-12-23 |
艾伯维公司 |
吡啶cdk9激酶抑制剂
|
|
WO2014139328A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
|
|
WO2014160028A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Pyrrolopyrimindine cdk9 kinase inhibitors
|
|
AU2014231567A1
(en)
|
2013-03-14 |
2015-10-01 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
|
|
US20140274896A1
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
JP6435315B2
(ja)
*
|
2013-03-15 |
2018-12-05 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
高活性抗新生物薬及び抗増殖剤
|
|
ME03557B
(me)
|
2013-03-15 |
2020-07-20 |
G1 Therapeutics Inc |
Privremena zaštiтa normalnih ćelija током hemoterapije
|
|
CN105209073A
(zh)
|
2013-03-21 |
2015-12-30 |
诺华股份有限公司 |
包含B-Raf抑制剂和第二抑制剂的组合疗法
|
|
ES2782003T3
(es)
|
2013-04-16 |
2020-09-09 |
Memorial Sloan Kettering Cancer Center |
Compañero de diagnóstico para inhibidores de CDK4
|
|
PL3033086T3
(pl)
|
2013-08-14 |
2022-01-31 |
Novartis Ag |
Terapia skojarzona do leczenia nowotworów złośliwych
|
|
EP3038652B1
(en)
*
|
2013-08-28 |
2018-03-21 |
Novartis AG |
Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
AR097894A1
(es)
*
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
US20160257688A1
(en)
*
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
CA2929620A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Novartis Ag |
Combination therapy comprising an inhibitor of jak, cdk and pim
|
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
|
WO2015095840A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
JP6675313B2
(ja)
|
2013-12-23 |
2020-04-01 |
ノバルティス アーゲー |
組合せ医薬
|
|
US20160339023A1
(en)
*
|
2013-12-23 |
2016-11-24 |
Fang Li |
Pharmaceutical Combinations
|
|
JP6263269B2
(ja)
|
2013-12-31 |
2018-01-17 |
シュエンジュウ・ファーマ・カンパニー・リミテッド |
キナーゼ阻害剤及びその使用
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3125920B1
(en)
|
2014-04-04 |
2020-12-23 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
|
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9717735B2
(en)
|
2014-04-17 |
2017-08-01 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
KR101864589B1
(ko)
*
|
2014-05-28 |
2018-07-04 |
상하이 포천 파마슈티컬 씨오 엘티디 |
특정한 단백질 키나아제 억제제
|
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
|
CA2963281A1
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
CA3000633C
(en)
|
2014-10-14 |
2023-10-03 |
The Regents Of The University Of California |
Use of cdk9 and brd4 inhibitors to inhibit inflammation
|
|
JP6951973B2
(ja)
|
2014-11-12 |
2021-10-20 |
シージェン インコーポレイテッド |
グリカン相互作用化合物及び使用方法
|
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
US9994579B2
(en)
|
2014-12-12 |
2018-06-12 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
US20160220569A1
(en)
*
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
JP2018509448A
(ja)
*
|
2015-03-25 |
2018-04-05 |
ノバルティス アーゲー |
組合せ医薬
|
|
BR112017021283A2
(pt)
|
2015-04-16 |
2018-06-26 |
Novartis Ag |
comprimido de ribociclib
|
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
MY192487A
(en)
|
2015-05-29 |
2022-08-23 |
Teijin Pharma Ltd |
Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
|
CN105037236B
(zh)
*
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
JP2018526377A
(ja)
|
2015-08-28 |
2018-09-13 |
ノバルティス アーゲー |
がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
|
|
ES2761885T3
(es)
*
|
2015-08-28 |
2020-05-21 |
Novartis Ag |
Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
|
|
US10328066B2
(en)
|
2015-08-28 |
2019-06-25 |
Novartis Ag |
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
EP3340987A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
|
EP3370719A1
(en)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
|
WO2017083582A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
|
WO2017161253A1
(en)
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
WO2017162215A1
(zh)
|
2016-03-25 |
2017-09-28 |
正大天晴药业集团股份有限公司 |
取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
|
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
|
CN109071552B
(zh)
*
|
2016-04-22 |
2022-06-03 |
达纳－法伯癌症研究所公司 |
细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
|
|
US10835535B2
(en)
|
2016-05-07 |
2020-11-17 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
|
CN108290899B
(zh)
*
|
2016-06-06 |
2020-09-18 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
|
SG10202110874TA
(en)
|
2016-06-07 |
2021-11-29 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
MX2019000200A
(es)
*
|
2016-07-01 |
2019-09-26 |
G1 Therapeutics Inc |
Agentes antiproliferativos basados en pirimidina.
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
BR112018077155A2
(pt)
|
2016-07-01 |
2019-04-02 |
G1 Therapeutics, Inc. |
processo para preparar um composto, e, composto
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
IL264950B2
(en)
|
2016-08-23 |
2024-01-01 |
Eisai R&D Man Co Ltd |
Combined treatments for the treatment of malignant liver cell carcinoma
|
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
|
CN109715163B
(zh)
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
BR112019005526A2
(pt)
|
2016-10-20 |
2019-06-18 |
Pfizer |
agentes antiproliferativos para tratamento de pah
|
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
WO2018094227A1
(en)
*
|
2016-11-17 |
2018-05-24 |
The University Of North Carolina At Chapel Hill |
Alkyl pyrrolopyrimidine analogs and methods of making and using same
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2018097295A1
(ja)
|
2016-11-28 |
2018-05-31 |
帝人ファーマ株式会社 |
ピリド［３，４－ｄ］ピリミジン誘導体又はその溶媒和物の結晶
|
|
US11084814B2
(en)
|
2016-11-28 |
2021-08-10 |
Teijin Pharma Limited |
Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
|
KR20190092478A
(ko)
|
2016-12-05 |
2019-08-07 |
쥐원 쎄라퓨틱스, 인크. |
화학요법 레지멘 동안의 면역 반응의 보존
|
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
|
JP2020506904A
(ja)
*
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
IL269357B1
(en)
|
2017-03-16 |
2024-06-01 |
Eisai R&D Man Co Ltd |
A combination of Era inhibitors and a CDK4/6 inhibitor to be used in a method to treat breast cancer
|
|
JP6878615B2
(ja)
|
2017-03-23 |
2021-05-26 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． |
Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
|
TW201906818A
(zh)
|
2017-05-31 |
2019-02-16 |
美商５１１製藥公司 |
新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
KR102659211B1
(ko)
|
2017-06-29 |
2024-04-18 |
쥐원 쎄라퓨틱스, 인크. |
G1t38의 형체 형태 및 그의 제조 방법
|
|
MX2020001253A
(es)
|
2017-08-03 |
2020-07-13 |
Novartis Ag |
Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor de quinasa dependiente de ciclina.
|
|
ES2968174T3
(es)
|
2017-08-25 |
2024-05-08 |
Assia Chem Ind Ltd |
Forma en estado sólido de succinato de ribociclib
|
|
EP3676404A1
(en)
|
2017-08-31 |
2020-07-08 |
Novartis AG |
Methods of selecting a treatment for cancer patients
|
|
CN111164085B
(zh)
*
|
2017-09-29 |
2023-04-04 |
杭州领业医药科技有限公司 |
瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
|
|
WO2019082143A1
(en)
|
2017-10-27 |
2019-05-02 |
Fresenius Kabi Oncology Ltd. |
IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS
|
|
US11179365B2
(en)
|
2017-11-16 |
2021-11-23 |
Novartis Ag |
Pharmaceutical combination comprising LSZ102 and ribociclib
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
WO2019123364A1
(en)
|
2017-12-22 |
2019-06-27 |
Shilpa Medicare Limited |
Novel polymorphs of ribociclib mono succinate
|
|
RU2020124138A
(ru)
|
2017-12-22 |
2022-01-24 |
Хиберселл, Инк. |
Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
|
|
WO2019133864A1
(en)
|
2017-12-29 |
2019-07-04 |
Accutar Biotechnology |
DUAL INHIBITORS OF PARP1 and CDK
|
|
JP2021509680A
(ja)
|
2018-01-08 |
2021-04-01 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｇ１ｔ３８の優れた投与レジメン
|
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
|
TW201940166A
(zh)
*
|
2018-01-29 |
2019-10-16 |
美商貝達醫藥公司 |
作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
|
|
US11174252B2
(en)
|
2018-02-15 |
2021-11-16 |
Nuvation Bio Inc. |
Heterocyclic compounds as kinase inhibitors
|
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
US10723739B2
(en)
|
2018-05-14 |
2020-07-28 |
Apotex Inc. |
Processes for the preparation of Ribociclib and intermediates thereof
|
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CN112839657A
(zh)
|
2018-08-24 |
2021-05-25 |
G1治疗公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
|
CA3112496A1
(en)
*
|
2018-09-13 |
2020-03-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
|
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
JP7460644B2
(ja)
|
2018-10-31 |
2024-04-02 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
|
US20230065740A1
(en)
*
|
2018-12-28 |
2023-03-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
US20220056037A1
(en)
*
|
2018-12-28 |
2022-02-24 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
CA3124015A1
(en)
|
2019-01-23 |
2020-07-30 |
Novartis Ag |
New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
|
|
BR112021015632A2
(pt)
|
2019-02-12 |
2021-10-05 |
Novartis Ag |
Combinação farmacêutica que compreende tno155 e ribociclibe
|
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
|
TW202100184A
(zh)
|
2019-05-20 |
2021-01-01 |
瑞士商諾華公司 |
Mcl-1抑制劑抗體－藥物結合物及使用方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
WO2020245664A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Step Pharma S.A.S. |
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
JP2022553832A
(ja)
*
|
2019-11-07 |
2022-12-26 |
クリネティックス ファーマシューティカルズ，インク． |
メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
|
|
AU2020405427A1
(en)
|
2019-12-16 |
2022-07-14 |
Lunella Biotech, Inc. |
Selective CDK4/6 inhibitor cancer therapeutics
|
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CA3161892A1
(en)
|
2019-12-23 |
2021-07-01 |
Jie Fan |
Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
|
|
CN114245753A
(zh)
*
|
2020-03-27 |
2022-03-25 |
江苏康宁杰瑞生物制药有限公司 |
用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
|
|
WO2021229439A1
(en)
|
2020-05-12 |
2021-11-18 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|
|
JP7406008B2
(ja)
*
|
2020-05-12 |
2023-12-26 |
蘇州阿尓脈生物科技有限公司 |
Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
|
|
US20230219961A1
(en)
*
|
2020-05-12 |
2023-07-13 |
Suzhou Alphama Biotechnology Co., Ltd. |
Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
|
|
AU2021273744A1
(en)
|
2020-05-19 |
2022-12-08 |
G1 Therapeutics, Inc. |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
|
AU2021385349A1
(en)
|
2020-11-24 |
2023-06-22 |
Les Laboratoires Servier |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
AU2021388021A1
(en)
|
2020-11-24 |
2023-06-22 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
EP4288434A1
(en)
|
2021-02-02 |
2023-12-13 |
Les Laboratoires Servier |
Selective bcl-xl protac compounds and methods of use
|
|
WO2022207788A2
(en)
|
2021-04-01 |
2022-10-06 |
Krka, D.D., Novo Mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117177752A
(zh)
|
2021-05-05 |
2023-12-05 |
诺华股份有限公司 |
用于治疗mpnst的化合物和组合物
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202320795A
(zh)
|
2021-07-26 |
2023-06-01 |
美商凱爾科迪股份有限公司 |
使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
|
|
KR20240041340A
(ko)
*
|
2021-07-27 |
2024-03-29 |
보로노이 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
|
TW202329977A
(zh)
|
2022-01-25 |
2023-08-01 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
WO2023196518A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
|
WO2023196517A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2023225336A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
|
WO2024086361A1
(en)
*
|
2022-10-21 |
2024-04-25 |
Novartis Ag |
Molecular glue degrader compounds and uses thereof
|
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
|
WO2024115680A1
(en)
|
2022-12-01 |
2024-06-06 |
Krka, D.D., Novo Mesto |
Ribociclib salts and formulations thereof
|
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|
